Tocilizumab (International)
In the US, Tocilizumab (tocilizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat COVID-19, Cytokine Release Syndrome, Giant Cell Arteritis, Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Still's Disease, Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L04AC07
CAS registry number (Chemical Abstracts Service)
0375823-41-9
Chemical Formula
C6428-H9976-N1720-O2018-S42
Molecular Weight
144985
Therapeutic Categories
Immunosuppressant
Monoclonal antibody
Chemical Name
immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide wit human-mouse monoclonal MRA kappa-chain, dimer (WHO)
Foreign Names
- Tocilizumabum (Latin)
- Tocilizumab (German)
- Tocilizumab (French)
- Tocilizumab (Spanish)
Generic Names
- Tocilizumab (OS: USAN)
- Tocilizumab (Genetical Recombination) (OS: JAN)
- Atlizumab (IS)
- MRA (IS)
- R-1569 (IS)
Brand Names
- Actembra
Roche, Egypt - Actemra
Chugai, Georgia; Chugai Pharma, Oman; Chugai Pharmaceutical, Japan; F. Hoffmann-La Roche, Macedonia; Galenika AD, Serbia; Genentech, United States; Hoffmann-La Roche, Canada; Productos Roche, Chile; Roche, Armenia; Roche, Netherlands Antilles; Roche, Argentina; Roche, Aruba; Roche, Azerbaijan; Roche, Bosnia & Herzegowina; Roche, Belarus; Roche, Ecuador; Roche, Hong Kong; Roche, India; Roche, Kyrgyzstan; Roche, Moldova; Roche, Myanmar; Roche, Malaysia; Roche, New Zealand; Roche, Oman; Roche, Peru; Roche, Philippines; Roche, Paraguay; Roche, Russian Federation; Roche, Thailand; Roche, Turkmenistan; Roche, Tunisia; Roche, Uruguay; Roche, Vietnam; Roche, South Africa; Roche D.O.O., Serbia; Roche Products, Australia; Vetter, Georgia; Vetter, Russian Federation; Roche Pharma Schweiz, Switzerland - ACTEMRA
Roche Pharmaceutical, China - Actemra 162mg
Roche, Israel - Actemra 200mg/10ml
Roche, Turkey - Actemra 20mg/ml
Roche, Israel - Actemra 400mg/20ml
Roche, Turkey - Actemra 80mg/4ml
Roche, Turkey - Acterma
Chugai Pharma, Kenya; Roche, Brazil - Acterma SC
Roche, Brazil - Aktempa
Roche, Ukraine - Roaccutane
Roche, Cyprus - RoActemra
Hoffmann-La Roche Ltd, Latvia; Roche, Belgium; Roche, Czech Republic; Roche, Denmark; Roche, Estonia; Roche, Spain; Roche, Finland; Roche, France; Roche, Greece; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Lithuania; Roche, Mexico; Roche, Norway; Roche, Poland; Roche, Sweden; Roche - Germania, Romania; Roche Products, United Kingdom; Roche Registration, Netherlands; Roche Registration Limited, Iceland; Roche Registration, Slovenia - RoActemra 162 mg
Roche, Hungary - RoActemra 162mg
Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria - RoActemra 20 mg/ml
Roche, Hungary - RoActemra 20mg/ml
Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria
Glossary
| Term | Definition |
|---|---|
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.